- Conditions
- Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Questionnaire Administration, Ropeginterferon Alfa-2B
- Procedure · Other · Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–78
of 78
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
- Interventions
- Luspatercept
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,013 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 155
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Pacritinib, Best Available Therapy
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 50
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more
- Conditions
- Myeloproliferative Neoplasm, Chronic Phase Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia
- Interventions
- Online Mindfulness Meditation, Internet-Based Webinars
- Behavioral · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Itacitinib, Ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 19
- States / cities
- Tempe, Arizona • Orange, California • Aurora, Colorado + 16 more
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MDS/MPN)
- Interventions
- ADCT-301
- Drug
- Lead sponsor
- Gwynn Long, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina